Though anti-CTLA-4 and anti-PD-1/PD-L1 are the most clinically utilized immune checkpoint antibodies, there has been robust investigation into the effectiveness of other immune checkpoint targeting antibodies to stimulate an anti-tumour immune response. Here, CTLA4 is linked to neoplasm.